Description

PT-141 (bremelanotide) is a synthetic cyclic compound and melanocortin receptor agonist studied in preclinical and clinical research settings. Unlike compounds that act on vascular pathways, PT-141 is of research interest for its activity at melanocortin receptors in the central nervous system, and it has been studied in models exploring pathways related to sexual motivation and arousal —distinguishing its proposed mechanism from PDE5 inhibitors, which act peripherally on blood flow.

A bremelanotide-based product (Vyleesi) has received FDA approval as a prescription treatment
for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
This product is referenced here for scientific context only. It is a distinct, prescription
pharmaceutical product; the compound offered here is sold strictly as a laboratory research reagent
and is not equivalent to, a substitute for, or intended to be used as that approved product.

• For Research use only
• Not for human use
• 99% Pure
• Independent Lab Tested